CARLSBAD, Calif.--(BUSINESS WIRE)--April 11, 2006--SkinMedica, Inc., a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases and improve the appearance of skin, announced today the closing of an $11.2 million private placement of its Series E-1 preferred stock. Montagu Newhall Associates, a new investor, led the round and existing investors Domain Associates, Apax Partners, Perseus-Soros Biopharmaceutical Fund, HealthCare Ventures, EuclidSR Partners and Montreux Equity Partners also participated.
